The U.S. Food and Drug Administration approved Qfitlia for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors. The FDA granted Qfitlia Orphan Drug and Fast Track designations for this application. The FDA granted the approval of Qfitlia to Sanofi (SNY).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Biotech Alert: Searches spiking for these stocks today
- Regeneron (NASDAQ:REGN) and Sanofi Get Japan Green Light for Smokers’ Lung Disease Treatment
- Regeneron, Sanofi announce Dupixent authorization in Japan
- RFK Jr. plans to cut 10,000 jobs in HHS, WSJ reports
- Sanofi’s Tolebrutinib and Chlamydia Vaccine Achieve Regulatory Milestones